Table 4 Adverse events occurring in more than one patient in any treatment group up to 100 days post first transplantation
Comparison 1 | Comparison 2 | Comparison 3 | ||||
|---|---|---|---|---|---|---|
Adverse event standard organ class, n (%) preferred term | G-CSF + plerixafor (N = 70) | G-CSF alone (N = 36) | G-CSF + plerixafor (N = 124) | G-CSF + chemotherapy (N = 124) | G-CSF + plerixafor + chemotherapy (N = 130) | G-CSF + chemotherapy (N = 130) |
Any adverse event up to 100 days post transplantation | 37 (52.9) | 19 (52.8) | 66 (53.2) | 62 (50.0) | 55 (42.3) | 68 (52.3) |
Infections and infestations | 32 (45.7) | 13 (36.1) | 56 (45.2) | 51 (41.1) | 42 (32.3) | 59 (45.4) |
Bacterial infections | 16 (22.9) | 8 (22.2) | 29 (23.4) | 31 (25.0) | 33 (25.4) | 36 (27.7) |
Blood and lymphatic disorders | 5 (7.1) | 3 (8.3) | 8 (6.5) | 5 (4.0) | 2 (1.5) | 3 (2.3) |
Gastrointestinal disorders | 2 (2.9) | 1 (2.8) | 4 (3.2) | 3 (2.4) | 3 (2.3) | 4 (3.1) |
General disorders and administration site disorders | 8 (11.4) | 1 (2.8) | 11 (8.9) | 14 (11.3) | 21 (16.2) | 17 (13.1) |
Metabolism and nutritional disorders | 0 | 0 | 0 | 2 (1.6) | 0 | 2 (1.5) |
Renal and urinary disorders | 1 (1.4) | 1 (2.8) | 2 (1.6) | 1 (0.8) | 3 (2.3) | 2 (1.5) |
Vascular disorders | 0 | 1 (2.8) | 0 | 1 (0.8) | 2 (1.5) | 2 (1.5) |
Cardiac disorders | 0 | 0 | 0 | 2 (1.6) | 1 (0.8) | 3 (2.3) |
Nervous system disorders | 0 | 0 | 1 (0.8) | 0 | 2 (1.5) | 0 |
Respiratory, thoracic, and mediastinal disorders | 0 | 0 | 0 | 1 (0.8) | 3 (2.3) | 1 (0.8) |
Skin and subcutaneous disorders | 0 | 0 | 0 | 0 | 2 (1.5) | 0 |
